Evidence map›Paper›PMID 39863408›Full record

ArticleBMJ open2025

Protocol for a systematic review and individual participant data meta-analysis for risk factors for lung cancer in individuals with lung nodules identified by low-dose CT screening.

Panos Alexandris, Samantha Quaife, Christine D Berg, Matthew Callister, Philip Aj Crosbie, Michael Pa Davies, Harry J de Koning, John K Field, Mark M Hammer, Carolyn Horst and 5 more

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Panos AlexandrisCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK p.alexandris@qmul.ac.uk.ORCID http://orcid.org/0000-0002-4489-0282
Samantha QuaifeCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Christine D BergUS National Cancer Institute (Retired), Rockville, Maryland, USA.
Matthew CallisterDepartment of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Philip Aj CrosbieDivision of Immunology, Immunity to Infection & Respiratory Medicine, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-8941-4813
Michael Pa DaviesDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, UK.
Harry J de KoningDepartment of Public Health, Erasmus Medical Center, Rotterdam, Netherlands.
John K FieldDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, UK.
Mark M HammerDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Carolyn HorstSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Sam JanesLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK.
Arjun NairNHS Foundation Trust, University College Hospital, London, UK.
Robert C RintoulDepartment of Thoracic Oncology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Rhian GabeCentre for Evaluation and Methods, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Stephen DuffyCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0003-4901-7922

Funding

Optimizing Lung Cancer Screening Nodule EvaluationR01CA260889 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KONG, CHUNG YIN, SIGEL, KEITH MAGNUS · 2021 to 2025
$3.5M
NCI NIH HHS R01 CA260889
6 · The paper itself

Abstract

backgroundWorldwide, lung cancer (LC) is the second most frequent cancer and the leading cause of cancer related mortality. Low-dose CT (LDCT) screening reduced LC mortality by 20-24% in randomised trials of high-risk populations. A significant proportion of those screened have nodules detected that are found to be benign. Consequently, many individuals receive extra imaging and/or unnecessary procedures, which can have a negative physical and psychological impact, as well as placing a financial burden on health systems. Therefore, there is a need to identify individuals who need no interval CT between screening rounds. METHODS AND ANALYSIS: The aim of this study is to identify risk factors predictive of LC, which are known at the time of the scan, in patients with LDCT screen-detected lung nodules. The MEDLINE and EMBASE databases will be searched and articles that are on cohorts or mention cohorts of screenees with nodules will be identified. A data extraction framework will ensure consistent extraction across studies. Individual participant data (IPD) will be collected to perform a one-stage IPD meta-analysis using hierarchical univariate models. Clustering will be accounted for by having separate intercept terms for each cohort. Where IPD is not available, the effects of risk factors will be extracted from publications, if possible. Effects from IPD cohorts and aggregate data will be reported and compared. The PROBAST (Prediction model Risk Of Bias ASsessment Tool) will be used for assessment of quality of the studies. ETHICS AND DISSEMINATION: Ethical approval was not required as this study is a secondary analysis. The results will be disseminated through publication in peer-reviewed journals and presentations at relevant conferences. PROSPERO REGISTRATION NUMBER: CRD42022309515.

Indexed as

Early Detection of CancerLung NeoplasmsMultiple Pulmonary NodulesTomography, X-Ray ComputedHumansMeta-Analysis as TopicResearch DesignRisk FactorsSystematic Reviews as TopicLung DiseasesMeta-AnalysisSystematic Review

Identifiers

PMID39863408
PMCPMC11784322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.